Ofev (nintedanib) — Medica

Initial criteria

• age ≥ 18 years
• Forced vital capacity (FVC) ≥ 40% of predicted value
• Diagnosis confirmed by ONE of the following: findings on high-resolution computed tomography indicating usual interstitial pneumonia OR surgical lung biopsy demonstrating usual interstitial pneumonia
• Medication is prescribed by or in consultation with a pulmonologist

Reauthorization criteria

• age ≥ 18 years
• Patient has experienced a beneficial response to therapy over the last year while receiving Ofev (examples: reduction in anticipated decline in FVC, six-minute walk distance, and/or number or severity of IPF exacerbations)
• Medication is prescribed by or in consultation with a pulmonologist

Approval duration

1 year